Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Exposure-time profile of SDX-7320 and SDX-7539 in cycle 1 (<i>n</i> = 5) in patients dosed at 49 mg/m<sup>2</sup> SDX-7320. Plasma samples were prepared from blood drawn at the indicated times postdose. The levels of SDX-7320 and the small molecule SDX-7539 were meas...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Monica M. Mita (21585118) (author)
Další autoři: Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Vydáno: 2025
Témata:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Protein biomarkers
Pharmacology
Pharmacokinetics and pharmacodynamics
Phase I Clinical Trials
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky